RU2406513C1 - Method of treating helminthiases in mammals - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine. Method lies in the following: dehelminthisation of animal, which needs such treatment, is carried out by introduction of antihelminthic of avermectin series. Additionally before and after dehelminthisation therapeutically efficient dose of Roncoleukin is introduced subcutaneously.

EFFECT: as a result of treatment animals get rid of helminthes a week earlier, treatment efficiency increases, contamination of environment with eggs and larvae of helminthesis reduced, toxic and immunosuppressing effect of parasites and antihelminthic avermectin series decreases.

5 cl, 2 tbl, 2 ex

Description

Field of Invention

The invention relates to veterinary medicine, relates to a comprehensive therapeutic and prophylactic method and can be used to treat helminthiasis in mammals.

State of the art

Helminthiasis of animals is a serious problem in animal husbandry. In the digestive canal of animals, a large number of helminths belonging to different types and classes can parasitize. Among them, the most common are alfortiosis, delafondiosis, strongilosis, trichonemiasis, strongyloidosis, anoplocephalidoses, which can affect up to 100% of the livestock. Helminthiases cause severe endotoxemia, allergic reactions, secondary immunodeficiency states. This leads to a decrease in the resistance of the livestock to infectious agents, inefficiency of vaccinations, exacerbation of chronic diseases of infectious etiology. This negatively affects the quantity and quality of milk, meat, fur obtained from animals, as well as the offspring of animals.

For the treatment of helminth infections in mammals, various anthelmintics are used, as well as chemical preparations with anthelmintic activity. The effectiveness of such treatment usually does not exceed 70-80% and is short-term (Arkhipov I.A. Influence of the massive use of anthelmintics on the environment. // "New Pharmacological Drugs in Veterinary Medicine": Mater. 12th Int., Interuniversity, scientific. Practical Conf. - SPb., 2000. - P.82-83; Suleymanov GA, Sidorkin VA The effectiveness of ivermek in equine paraskariosis // "Theory and practice of controlling parasitic diseases": Mater, dokl. .cof. - M., 2007, - Issue 8. S.345-347). Moreover, the use of anthelmintics, including those with high efficacy, is associated with the manifestation of side effects of their action, such as endotoxemia, a slowdown in weight gain, an increase in preimplantation mortality, the development of neurosis, etc. (Byakova O.V., Belozerov S .N., Skornekova OO, Therapeutic evaluation of Equisect-2 antiparasitic paste in horses. // "Theory and practice of controlling parasitic diseases." // Mater. Dokl. Scientific. Coffee. - M., 2007, - Issue 8. P.52-53; Arkhipov I.A., Influence of mass application of antigel Intikov on the environment. // "New pharmacological agents in veterinary medicine": Mater. 12th international., inter-university scientific and practical conference - St. Petersburg, 2000. - P.82-83; Maksimenko S.N. The study of subacute toxicity of microstimulated albendazole. // "Theory and practice of combating parasitic diseases" - Mater. Dokl. Scientific kof. - M., 2007. - Issue 8, p.190-192; Petrov Yu.F. Immunity at invasive diseases of farm animals. - M., 1984 - 17 p.).

In this regard, there is a need to find new methods for the treatment of mammalian helminthiases.

The objective of the present invention is to reduce the incidence of mammals, reduce the time of deworming, that is, increase the effectiveness of treatment with anthelmintic, as well as increase the safety of young animals.

This problem is solved by the method of the present invention.

SUMMARY OF THE INVENTION

A method is proposed for treating helminthiases in mammals, in particular horses, in which deworming of an animal in need of such treatment is carried out by the introduction of an anthelmintic of the avermectin series, while the animals are additionally injected subcutaneously with Roncoleukin ^® before and after deworming.

DETAILED DESCRIPTION OF THE INVENTION

One of the most highly effective anthelmintics is the avermectin series. These drugs are widely used for infection with both exo- and endoparasites. Substances based on avermectins include, in particular, aversectin C (preparations "Equisect ^® paste" and "Univerm ^® ") and ivermectin (preparation "Equalan ^® " and "Alezan ^® "). These drugs are used for the treatment and prevention of various helminthiases in horses, cattle, sheep, goats, camels, bison, fur animals and rabbits.

In one embodiment of the present invention, a drug ^"® Ekvisekt paste". The animal to be treated is preferably a horse.

The drug “Equisect ^® paste” contains 1% of the natural avermectin complex Aversectin C. as an active ingredient. The drug is released in a syringe dispenser of 14 g each. It is recommended for the treatment and prevention of horses with strongyloidosis, strongylatosis, parascariosis, oxyurosis, gastrointestinal gadfly. The drug is squeezed onto the root of the tongue, individually, at a dose of 2 g / 100 kg MT (0.2 mg / kg MT DV). A syringe dispenser is inserted into the interdental space and the head of the animal is raised for several seconds to avoid spitting. The required volume of equisect paste is established by moving the nut along the syringe rod. One division of the syringe is designed for 100 kg of MT of the animal. One syringe is designed to handle horses weighing 700 kg. In excessive doses, as well as in depleted and sick animals, the drug can cause toxic reactions.

It was unexpectedly found that the combination of avermectin anthelmintic with the Roncoleukin ^® immunostimulator significantly increases the effectiveness of deworming, that is, this combination has a synergistic effect.

Roncoleukin ^® (drug registration number 95/249/5) is a human recombinant interleukin-2 preparation. Currently, recombinant human interleukin-2 is obtained from a yeast strain Saccharomyces cerevisiae, in the genetic apparatus of which the human interleukin-2 gene is integrated. The active substance Roncoleukin ^® - recombinant human yeast interleukin-2 - is a polypeptide consisting of 133 amino acids with a molecular weight of 15.4 kDa, which is a structural and functional analogue of endogenous interleukin-2 (SU 1770359; Popovich AM, Egorova V.N. Interleukin-2: clinical experience // St. Petersburg, 2005.36 p.). Despite the fact that recently in the domestic literature there have been reports of the use of this drug for mild immunocorrection in diseases of an infectious and non-infectious etiology, there are no reports of its use in combination with anthelmintics for the complex treatment of helminthiasis. Therefore, its effect on the treatment of helminthiasis precisely with the help of an avermectin anthelmintic could not be obvious to a specialist.

As a result of the introduction of Roncoleukin ^®, cellular and humoral factors of immunity are activated and animals are released one week earlier from helminths in comparison with the known method.

Thanks to the proposed treatment regimen, the length of the parasite’s stay in mammals is reduced, the toxic and immunosuppressive effects of parasites and anthelmintics are reduced, the deworming efficiency is increased, and the environmental pollution of eggs and larvae of parasites is reduced.

The following are examples that do not limit the scope of the invention, but serve only to illustrate the implementation of the invention in the form of one of its private embodiments.

Example 1

In this example, a comparatively known method for treating equine helminthiasis using aversectin C and the method of the present invention are described.

A study of the effectiveness of different methods of horse therapy in mixed helminthiases was carried out at a stud farm in the Bobrovsky district of the Voronezh region. In the experiments, horses of 1-1.5-year-old age were selected, selected on the principle of paired analogues, most susceptible to infection with helminths. Preliminary helminthological studies using the Darling method isolated eggs of various types of intestinal nematodes, roundworm, oxiuride, strongillate and anoplocephalus. 10 horses were taken to each group:

Group I - animals with mixed helminthiases. They were not given drugs

Group II - sick animals that were injected with the anthelmintic aversectin C (Equisect ^® paste) at a dose of 1 ml / 100 kg MT once at the root of the tongue,

Group III - sick animals, which 24 hours before deworming and 24 hours after it were injected subcutaneously with Roncoleukin ^® (i.e., recombinant human yeast interleukin-2 as a drug) at a dose of 1000 IU / kg MT. Anthelmintic aversectin C was administered in the same way as group II, i.e., at a dose of 1 ml / 100 kg MT once.

The functional state of the immune system in terms of blood counts was also taken into account. Blood and feces were taken in the morning before feeding. The first time before the administration of drugs and then on 6 and 15 days after treatment. The results of helminthological studies and the effectiveness of deworming methods were taken into account by the “control test” method by comparing the indicators of intensity and intensity of invasion in animals of experimental and control groups. The intensity of invasion (II) (the number of parasites per 1 g of feces), the intensity of the invasion (EI), the intensity (IE), and the extensibility (EE) were determined. The results are shown in Table 1.

TABLE 1 Groups before drug administration after the introduction of drugs on the 6th day after drug administration on the 15th day AI EI (%) AI EI (%) IE (%) EE (%) AI EI (%) IE (%) EE (%) I 351.4 ± 18.0 one hundred 356.3 ± 18.2 one hundred 0 0 354.8 ± 17.6 one hundred 0 0 II 388.6 ± 18.9 one hundred 115.7 ± 8.5 56.7 70,2 43.3 103.5 ± 4.1 21.8 * 73.3 78,2 III 403.8 ± 17.2 one hundred 57.9 ± 4.0 * 11.7 * 85.7 88.3 * 5.4 ± 0.08 * 0.2 * 98.6 99.8 * p <0.01 compared with groups I and II

The method of the present invention allows to increase the effectiveness of deworming up to 99.8%, which is 21.6% higher than the effectiveness of the known method using anthelmintic separately.

Example 2

The effect of the method of the present invention on the immune system of horses was analyzed according to the structural and functional state of the cells of the immune system of sick animals after deworming by the known method and method of the present invention. The results are shown in Table 2.

After applying the method according to the invention, there is a clear tendency to activate all immunity indices indicated in Table 2 (* p <0.01) in group III with respect to I and II: the content of T-helpers, activated T-lymphocytes, the total number of lymphocytes in the leukoformula increased more than 2 times (* p <0.01), the number of CECs decreased 2.7 times and T-suppressors 2.4 times (* p <0.01).

Thus, the method of the present invention unexpectedly significantly increases the effectiveness of deworming compared with the use of a single anthelmintic and leads to the release of animals from helminths a week earlier.

TABLE 2 Groups Before drug administration After drug administration T-suppressors,% T-helpers,% T-lymphocyte
You are active. % Circulating immune complexes (CEC) The total number of lymph.,% T-sp.,% T-help.% T-lymph., Active.% CEC, cu The total number of lymph.% I 41.83 ± 12.3 20.3 ± 3.7 24.0 ± 5.0 231.3 ± 8.7 20.6 ± 4.7 43.82 ± 13.2 20.0 ± 3.0 24.0 ± 5.1 281.2 ± 9.5 20.5 ± 4.1 eleven 41.80 ± 12.3 20.3 ± 3.4 24.1 ± 5.0 238.9 ± 8.8 19.6 ± 4.4 37.06 ± 12.2 20.5 ± 3.2 24.7 ± 4.4 245.4 ± 8.7 25.3 ± 4.9 III 43.76 ± 12.4 20.1 ± 3.2 24.0 ± 5.1 240.3 ± 8.7 19.2 ± 4.8 18.24 ± 3.8 * 42.7 ± 7.3 * 52.7 ± 12.4 * 88.6 ± 3.3 * 40.7 ± 9.7 * * p <0.01 compared with groups I and II

Claims (5)

1. A method of treating helminthiases in mammals, in which deworming of an animal in need of such treatment is carried out by administering an anthelmintic of the avermectin series, characterized in that the animals are additionally subcutaneously administered with a therapeutically effective dose of Roncoleukin before and after deworming. 2. The method according to claim 1, characterized in that said anthelmintic is aversectin C. 3. The method according to claim 1, characterized in that said mammal is a horse. 4. The method according to claim 1, characterized in that Roncoleukin is administered to the animal at a dose of 1000 IU / kg body weight. 5. The method according to claim 1, characterized in that Roncoleukin is administered to the animal 24 hours before deworming and 24 after deworming.